AMETEK(AME) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - AMETEK reported record sales of $2 billion in Q4 2025, a 13% increase from Q4 2024, with organic sales up 5% and acquisitions contributing 7% [6][5] - Operating income reached a record $523 million, a 12% increase year-over-year, with operating margins at 26.2% and core margins at 27.6%, up 100 basis points [7][8] - EBITDA for the quarter was a record $618 million, up 10% from the previous year, with EBITDA margins at 30.9% [7] - Diluted earnings per share were a record $2.01, up 7% from Q4 2024, exceeding guidance [8] - Free cash flow was a record $527 million, up 6% year-over-year, with a conversion rate of 132% [8][24] Business Line Data and Key Metrics Changes - The Electronic Instruments Group (EIG) achieved sales of $1.37 billion, up 13% from the previous year, with organic sales up 2% and acquisitions contributing 10 points [9] - The Electromechanical Group (EMG) reported sales of $629 million, a 15% increase, with organic sales up 14% and operating income up 28% [10] - For the full year 2025, AMETEK established records for sales, operating income, and diluted earnings per share, with total sales of $7.4 billion, up 7% from 2024 [11] Market Data and Key Metrics Changes - Overall sales in the U.S. were up mid-single digits, while Europe saw low single-digit growth, and Asia experienced a 10% increase, driven by strong performance in China [41][43] - The process businesses grew mid-teens in Q4, with low single-digit organic growth, while Aerospace & Defense businesses saw low double-digit growth [40] Company Strategy and Development Direction - AMETEK announced the acquisition of LKC Technologies, enhancing its med tech exposure and broadening its ophthalmic portfolio [12][13] - The company plans to invest an incremental $100 million in growth initiatives in 2026, focusing on research, development, and technology innovation [15] - AMETEK aims to maintain a disciplined approach to capital deployment, prioritizing acquisitions while also considering share repurchases and dividends [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to offset inflation and tariffs through pricing strategies, expecting continued strong performance in 2026 [30][31] - The outlook for 2026 includes expected sales growth in the mid- to high-single digits, with diluted earnings per share projected to be between $7.87 and $8.07 [18] - Management noted a strong pipeline of acquisition candidates and a favorable M&A environment, indicating readiness to deploy significant capital [14][85] Other Important Information - AMETEK's effective tax rate for Q4 was 16.3%, with expectations for 2026 between 18.5% and 19.5% [22] - The company reported total debt of $2.3 billion at year-end, with cash and cash equivalents of $458 million [24] Q&A Session Summary Question: Can you provide insights into the medical portfolio performance? - Management indicated that the broader healthcare exposure accounts for 21% of the business, with Paragon and Rauland showing low double-digit growth in Q4 and high single digits for the full year [28] Question: What is the outlook for strategic pricing going forward? - Management stated that they expect to maintain a positive price-cost spread in 2026, successfully offsetting inflation and tariffs [30] Question: Can you discuss the performance of the process businesses? - Management noted that process businesses grew mid-teens in Q4, driven by recent acquisitions, with expectations for low single-digit organic growth in 2026 [40] Question: What is the status of the FARO acquisition? - Management expressed confidence in the integration of FARO, expecting to double EBITDA margins from mid-teens to 30% within three years [70] Question: How is the M&A pipeline looking for 2026? - Management reported a strong pipeline of acquisition opportunities, including larger deals, and emphasized their readiness to act on high-quality candidates [94][85]